Items tagged with HIV coinfection
The incidence of tuberculosis among HIV-positive individuals with high CD4 counts: implications for policy (post)
Abstract
WHO confirms antiretroviral therapy reduces the risk of life-threatening HIV-related infections (post)
20 June 2016 - Adults and children with HIV who start antiretroviral therapy (ART) as early as possible reduce their risk of developing serious HIV-related infections, according to new findings published in the journal Clinical Infectious Diseases on 15 June 2016.
Strengthening immune defence may be solution for treating TB (post)
Researchers at Linköping University have made a discovery that could contribute to developing new vaccines and treatment alternatives for tuberculosis in the future. The results have been published in Scientific Reports.
Researcher receives grant to understand why some HIV+ individuals avoid 'duet of death' (post)
Case Western Reserve University School of Medicine experts and colleagues in the United States and Africa have received an $11 million, five-year NIH grant to understand why some people living with HIV in Africa avoid becoming infected with the bacterium that causes tuberculosis (TB) despite exposure to high-TB-risk circumstances.
Success against deadly drug-resistant TB in rural KwaZulu-Natal (post)
Tugela Ferry is a remote KwaZulu-Natal (KZN) district of 180,000 people that became infamous in 2006. Here it was discovered that 53 people had contracted a type of tuberculosis (TB) that was resistant to most anti-TB medicines. All but one of the patients died. All those tested for HIV were positive.
Preventable deaths of children with HIV (post)
According to the World Health Organization (WHO), 150,000 children with HIV under 15 years of age died of opportunistic infections in low-to-middle income countries in 2014 alone. But a study recently published in the journal of Clinical Infectious Diseases suggests that not only were many of these infections and deaths potentially preventable had the children received antiretroviral therapy (ART) to support their depleted immune systems, but doing so in future would result in annual savings of close to USD$ 18 million per year for health organizations around the world because they would reduce the costs of treating the diseases the children develop.
Daily TB treatment better than intermittent (post)
DURBAN, South Africa, July 21 – Patients diagnosed with tuberculosis as well as HIV do better in combating tuberculosis with an intensified daily regimen rather than intermittent therapy that delivers less medicine, researchers reported here.
High-dose rifampicin for TB treatment regimen may improve survival in people with low CD4 cell counts (post)
More aggressive TB treatment using high dose of rifampicin, in addition to ARV treatment, could reduce TB/HIV mortality among co-infected TB/HIV patients with a severe immunocompromised state, according to Corinne Merle of the London School of Hygiene & Tropical Medicine who presented the results of the three-arm RAFA trial last week at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa.
Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB (post)
Levofloxacin was safe and well tolerated in children with and without HIV in long-term use. The data provide additional support for its inclusion in paediatric TB treatment and prevention regimens. [1]
Does detectable CMV signal high mortality risk for older people with HIV and TB? (post)
A study conducted in a cohort of hospitalized adults with HIV-associated tuberculosis (TB) in Khayelitsha found that having a detectable cytomegalovirus (CMV) viral load was associated with higher mortality within the first 12 weeks on TB treatment, according to Amy Ward from the University of Cape Town, who presented the findings at the 21st International AIDS Conference last month in Durban.
Page 18 of 52 · Total posts: 0
←First 17 18 19 Last→